Scribe Therapeutics (NASDAQ:SCTX) Trading Up 5.4% – Time to Buy?

Posted by Geri Gentry on Sep 15th, 2026

Shares of Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) rose 5.4% during trading on Tuesday . The company traded as high as $31.15 and last traded at $31.01. Approximately 45,468 shares changed hands during trading, a decline of 79% from the average daily volume of 213,467 shares. The stock had previously closed at $29.42.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Leerink Partners assumed coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price target on the stock. Wall Street Zen raised Scribe Therapeutics to a “hold” rating in a report on Saturday, August 1st. Wells Fargo & Company initiated coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $60.00 target price on the stock. Guggenheim initiated coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $50.00 price target for the company. Finally, Zacks Research upgraded Scribe Therapeutics to a “hold” rating in a research report on Tuesday, September 1st. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $51.75.

Check Out Our Latest Analysis on SCTX

Scribe Therapeutics Trading Up 6.2%

Scribe Therapeutics (NASDAQ:SCTX – Get Free Report) last issued its earnings results on Wednesday, September 2nd. The company reported ($3.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.20) by $2.36. The business had revenue of $1.92 million for the quarter, compared to the consensus estimate of $3.10 million. On average, analysts forecast that Scribe Therapeutics Inc. will post -3.68 EPS for the current fiscal year.

Insider Activity at Scribe Therapeutics

In related news, Director Behzad Aghazadeh bought 7,905 shares of the stock in a transaction dated Tuesday, July 28th. The shares were purchased at an average price of $18.25 per share, with a total value of $144,266.25. Following the completion of the acquisition, the director owned 3,088,888 shares of the company’s stock, valued at $56,372,206. This represents a 0.26% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Bio Fund Ii L.P. Ah bought 333,333 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The shares were bought at an average price of $15.00 per share, with a total value of $4,999,995.00. Following the transaction, the insider owned 2,385,075 shares of the company’s stock, valued at $35,776,125. The trade was a 16.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders acquired 3,727,237 shares of company stock valued at $56,291,746.

About Scribe Therapeutics

(Get Free Report)

Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based genetic medicines. The company’s platform is designed to engineer gene-editing systems with the aim of improving precision, delivery and therapeutic performance for the treatment of serious diseases.

Its research includes engineered CRISPR enzymes, guide RNAs and other components intended for use in both in vivo and ex vivo gene-editing applications. Scribe has pursued programs in areas including genetic and neurological disorders, although the status and scope of individual development programs may change as research advances.

Founded in 2018, Scribe Therapeutics was established by researchers and entrepreneurs associated with the development of CRISPR technologies.